| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.aareydrugs.com | |
| Market Cap | 101.54 Cr. | |
| Enterprise Value(EV) | 123.67 Cr. | 2021-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 3.43 | Trailing Twelve Months Ending 2021-12 |
| Price-Earning Ratio (PE) | 11.66 | Trailing Twelve Months Ending 2021-12 |
| Industry PE | 29.26 | Trailing Twelve Months Ending 2021-12 |
| Book Value / Share | 45.06 | Trailing Twelve Months Ending 2021-12 |
| Price to Book Value | 0.89 | Calculated using Price: 40.00 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 2.54 Cr. | 25,384,684 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Aarey Drugs & Pharmaceuticals Ltd. was established in 1990. The company is engaged in the manufacturing of drugs and intermediates such as metronidazole, metronidazole benzoate, methyl, and nitro imidazole. The company is based in Thane, India. The company also export its products to various other countries like Germany, Sri Lanka, Pakistan, Nepal and a number of African countries and is looking to establish its trade relations in other parts of the world as well. Product range of the company includes: API/Intermediate
Drug deliveryPharmaceuticals / Therapeutics Therapeutic targets of the company's products are:
Recent development Aarey Drugs & Pharmaceuticals has recently informed that Atul A Zatakia has resigned from the Company as a Director with effect from March 01, 2009. |
||
Company Profile
Aarey Drugs & Pharmaceuticals Ltd. was established in 1990. The company is engaged in the manufacturing of drugs and intermediates such as metronidazole, metronidazole benzoate, methyl, and nitro imidazole. The company is based in Thane, India.
The company also export its products to various other countries like Germany, Sri Lanka, Pakistan, Nepal and a number of African countries and is looking to establish its trade relations in other parts of the world as well.
Product range of the company includes: API/Intermediate
Drug deliveryPharmaceuticals / Therapeutics
Therapeutic targets of the company's products are:
Recent development
Aarey Drugs & Pharmaceuticals has recently informed that Atul A Zatakia has resigned from the Company as a Director with effect from March 01, 2009.
| 1 Day |
|
+0.38% |
| 1 Week |
|
+6.27% |
| 1 Month |
|
-12.61% |
| 3 Month |
|
-9.33% |
| 6 Month |
|
+12.89% |
| 1 Year |
|
+26.91% |
| 2 Year |
|
+121.39% |
| 5 Year |
|
-64.94% |
| 10 Year |
|
+88.59% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 1.99 | 3.10 | 3.12 | 3.58 | 12.90 | 9.80 | 8.07 | 6.65 | 6.98 | |
| Return on Capital Employed (%) | 4.42 | 5.83 | 6.69 | 7.23 | 22.21 | 14.14 | 12.05 | 8.48 | 9.46 | |
| Return on Assets (%) | 0.68 | 0.98 | 0.98 | 1.07 | 4.09 | 3.96 | 4.15 | 3.41 | 3.05 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
| Shh. Funds | 33 | 35 | 35 | 37 | 49 | 80 | 87 | 92 | 99 | 104 | |
| Non Curr. Liab. | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 2 | 2 | ||
| Curr. Liab. | 73 | 72 | 80 | 88 | 92 | 88 | 58 | 100 | 133 | 158 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 107 | 107 | 115 | 125 | 143 | 170 | 146 | 194 | 233 | 264 | |
| Non Curr. Assets | 8 | 5 | 6 | 8 | 13 | 13 | 13 | 13 | 15 | 19 | |
| Curr. Assets | 99 | 102 | 109 | 117 | 130 | 157 | 133 | 181 | 218 | 245 | |
| Misc. Exp. not W/O | 0 | 0 | 0 | ||||||||
| Total Assets | 107 | 107 | 115 | 125 | 143 | 170 | 146 | 194 | 233 | 264 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
| Net Sales | 172 | 200 | 213 | 246 | 396 | 349 | 355 | 300 | 348 | 551 | |
| Other Income | 0 | 2 | 3 | 3 | 3 | 3 | 4 | 7 | 7 | 3 | |
| Total Income | 173 | 201 | 216 | 249 | 399 | 352 | 359 | 307 | 355 | 554 | |
| Total Expenditure | -170 | -198 | -212 | -245 | -386 | -341 | -347 | -297 | -344 | -539 | |
| PBIDT | 2 | 3 | 4 | 4 | 13 | 11 | 12 | 10 | 12 | 15 | |
| Interest | -1 | -1 | -1 | -2 | -4 | -2 | -2 | -2 | -2 | -2 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | |
| Taxation | 0 | 0 | 0 | -1 | -3 | -2 | -2 | -1 | -2 | -3 | |
| Exceptional Items | |||||||||||
| PAT | 1 | 1 | 1 | 1 | 5 | 6 | 7 | 6 | 7 | 9 | |
| Adjusted EPS | 0 | 1 | 1 | 1 | 3 | 3 | 3 | 2 | 3 | 4 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | -9 | 3 | 0 | 3 | 6 | 1 | -20 | 1 | 3 | 5 | |
| Cash Fr. Inv. | 0 | -3 | 2 | -2 | -3 | -5 | -1 | -1 | -1 | -3 | |
| Cash Fr. Finan. | 10 | -1 | -1 | -2 | -2 | 4 | 23 | -2 | -2 | -2 | |
| Net Change | 1 | -1 | 0 | -1 | 1 | -1 | 2 | -3 | 0 | 0 | |
| Cash & Cash Eqvt | 1 | 1 | 1 | 0 | 2 | 1 | 3 | 0 | 1 | 1 |
|
Fri, 29 Apr 2022
Statement Of Deviation(S) Or Variation (S) Under Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Statement of deviation(s) or variation (s) under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
|
Tue, 19 Apr 2022
Compliance Certificate Of Regulation 7(3) Of SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015 Compliance Certificate of Regulation 7(3) of SEBI ((Listing Obligations and Disclosures Requirements) Regulations 2015 |
|
Wed, 13 Apr 2022
Certificate Under Regulation 40(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015. Certificate under Regulation 40(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015. |
| Fri, 20 May 2022 |
Opening at High
|
High Decrease 1 Month
|
High Increase 2 Years
|
Black Marubozu
|
| Thu, 19 May 2022 |
|
Opening at High
|
Equities
M.F.
Sectors